A
Last Price
52 Week Range
€0.00 - €0.69
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | €1.62M |
EV | €1.57M |
Shares Outstanding | 6.23M |
Beta | 51.27 |
Industry | Medical - Distribution |
Analyst Rating | - |
Analyst Target Price | - |
Number of Analysts | 0 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -83556500.00% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y
A
Arzneiwerk AG VIDA
TLIK
Sector
Healthcare
Industry
Medical - Distribution
CEO
Knoche, Sascha
Employees
2
Website
www.arzneiwerk.agIPO Date
2000-01-14
Headquarters
Ordensmeisterstr. 15-16, Berlin, Berlin, 12099, Germany
The last closing price of Arzneiwerk AG VIDA (TLIK) is €0.26, reflecting a -31.58% change from the prior session. Last updated: February 13, 2026 at 11:31 AM Eastern Time
Review of Recent TLIK Stock Performance trends:Past 1 Month: Arzneiwerk AG VIDA (TLIK) shares changed by +4.00%.Past 3 Months: The stock recorded a change of -21.69%.Past 6 Months: TLIK shares posted a change of +30.00%. Last updated: February 15, 2026 at 5:23 PM Eastern Time
Over the last year, Arzneiwerk AG VIDA (TLIK) has established a 52-week price range between a high of €0.69 and a low of €0.00. This metric is essential for assessing the stock's annual volatility. Last updated: February 15, 2026 at 5:23 PM Eastern Time
Arzneiwerk AG VIDA (TLIK) is considered a high volatility stock. It has a beta of 51.27, which means it typically moves 51.27 times as much as the broader market. Over the past 52 weeks, TLIK has traded within a €0.00 – €0.69 range. Last updated: February 15, 2026 at 5:23 PM Eastern Time
A €1,000 investment in Arzneiwerk AG VIDA 5 years ago, when the stock was trading around €1.31, would be worth approximately €198.51 today, based solely on share price performance (excluding dividends). This represents a total return of -80.15% over the period, equivalent to a compound annual growth rate (CAGR) of -27.63%. Past performance reflects historical price movements only and does not imply future results. Last updated: February 15, 2026 at 5:23 PM Eastern Time
The current Arzneiwerk AG VIDA (TLIK) market capitalization is approximately €1.62M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Arzneiwerk AG VIDA's market cap fluctuates with changes in its share price and share count. Last updated: February 15, 2026 at 5:23 PM Eastern Time
In the most recently reported quarter, Arzneiwerk AG VIDA (TLIK) generated €28.22K in revenue, representing a -100.18% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: February 15, 2026 at 4:30 AM Eastern Time
In the most recently reported fiscal year, Arzneiwerk AG VIDA (TLIK) generated net income of €-0.84M, compared with €-1.89M in the prior fiscal year, representing a +55.86% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: February 15, 2026 at 4:30 AM Eastern Time
According to its latest quarterly filing, Arzneiwerk AG VIDA (TLIK) reported EBITDA of €-0.24M, representing a +6.33% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: February 15, 2026 at 4:30 AM Eastern Time
Based on the latest available data, Arzneiwerk AG VIDA (TLIK) is currently trading at a last twelve months (LTM) P/E ratio of -2.20x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: February 15, 2026 at 4:30 AM Eastern Time
In the most recently reported quarter, Arzneiwerk AG VIDA (TLIK) revenue was €28.22K. Earnings per share (EPS) for the quarter were €-0.05. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: February 15, 2026 at 4:30 AM Eastern Time
Arzneiwerk AG VIDA (TLIK) does not currently pay a dividend. Over the last twelve months (LTM), the company paid €0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: February 15, 2026 at 4:30 AM Eastern Time
Based on the latest available analyst coverage, Arzneiwerk AG VIDA (TLIK) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: February 15, 2026 at 4:30 AM Eastern Time
Like other publicly traded stocks, Arzneiwerk AG VIDA (TLIK) shares are bought and sold on stock exchanges such as DB and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Arzneiwerk AG VIDA (TLIK) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add TLIK to your watchlist.
Arzneiwerk AG VIDA trades under the ticker symbol TLIK on the DB stock exchange. The ticker TLIK is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
As of the most recently reported period, Arzneiwerk AG VIDA (TLIK) employs approximately 2 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: February 15, 2026 at 5:23 PM Eastern Time
Arzneiwerk AG VIDA (TLIK) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Arzneiwerk AG VIDA (TLIK) stock peers based on overlapping products, services, and competitive dynamics:Medios (ILM1)BMP Pharma Trading (BMP)Eastwood Bio-Medical Canada (EBM)New Ray Medicine International Holding (6108)Wellgistics Health (WGRX)160 Health International (2656)Koa Shoji Holdings (9273)Charmacy Pharmaceutical (2289) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Arzneiwerk AG VIDA.
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.